A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease

PURPOSE: To evaluate the safety and efficacy of topical TOP1630, a novel nonsystemic kinase inhibitor, in dry eye disease (DED). PATIENTS AND METHODS: A randomized, double-masked, parallel-group trial of 0.1% TOP1630 ophthalmic solution TID or placebo (vehicle without active drug) was conducted in D...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Mike, Ousler, George, Torkildsen, Gail, Walshe, Claire, Fyfe, Matthew C T, Rowley, Adele, Webber, Steve, Sheppard, John D, Duggal, Ajay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387610/
https://www.ncbi.nlm.nih.gov/pubmed/30858682
http://dx.doi.org/10.2147/OPTH.S189039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387610/
https://www.ncbi.nlm.nih.gov/pubmed/30858682
http://dx.doi.org/10.2147/OPTH.S189039

Ejemplares similares